You are here

Mark Surowiak

  • Director
215-854-4063
(add to contacts)

Biography

Mark is a Director in the Philadelphia office with over 15 years of experience in mergers & acquisitions, private placements and financial advisory services.   While Mark's primary focus includes clients in the health and medical industry, his experience spans a broad range of industries, including government and defense contracting, manufacturing and outsourced business services sectors.  Prior to investment banking, he enjoyed a career in the social services field.

Previously, Mark served over 10 years as a senior investment banking professional in Morgan Stanley Smith Barney’s Capital Strategies Group.  Over his career, Mark has focused on developing deep credentials and expertise in the sale and recapitalization of privately held businesses.

 

Education

Illinois State University - BS - Business Administration

Registrations & Affiliations

FINRA - Series 7, 63 and 79 Registered Securities Representative

Industry Coverage

Merger and acquisition (M&A) activity moderately increased in 2020, with 111 transactions compared to 103 in 2019.  Notably, while other industries experienced a steep pandemic-driven drop-off in deal activity during Q2, the Behavioral Healthcare Services industry remained relatively stable. The industry is expected to see strong growth in 2021, as COVID-19 has proved not only a physical health crisis, but a mental health crisis as well due to prolonged lockdowns, job losses, and social isolation.  Read more

COVID-19 has placed heightened focus on labor supply constraints in the Healthcare industry as hospitals struggle to meet the demand for care amid surging case volumes.  Healthcare staffing firms have played a critical role in efficiently scaling healthcare providers’ workforce requirements, while navigating a highly dynamic labor environment. Read more

Merger and acquisition (M&A) activity has slowed substantially in year-to-date (YTD) 2020 with seven transactions announced or completed compared to 25 transactions in YTD 2019.  However, as Q2 closes, the substantial amount of private equity dry powder presents a favorable backdrop for deal activity to rebound in the Healthcare Staffing industry.Read more